Jianzhijia Pharmaceutical Chain Group Future Growth
Future criteria checks 4/6
Jianzhijia Pharmaceutical Chain Group is forecast to grow earnings and revenue by 21% and 20% per annum respectively. EPS is expected to grow by 20.7% per annum. Return on equity is forecast to be 16.9% in 3 years.
Key information
21.0%
Earnings growth rate
20.7%
EPS growth rate
| Consumer Retailing earnings growth | 29.8% |
| Revenue growth rate | 20.0% |
| Future return on equity | 16.9% |
| Analyst coverage | Low |
| Last updated | 03 May 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 15,719 | 685 | N/A | 1,252 | 1 |
| 12/31/2025 | 13,920 | 601 | N/A | 1,073 | 2 |
| 12/31/2024 | 10,768 | 460 | N/A | 1,150 | 1 |
| 3/31/2024 | 9,228 | 390 | 468 | 793 | N/A |
| 12/31/2023 | 9,081 | 414 | 724 | 1,024 | N/A |
| 9/30/2023 | 9,305 | 446 | 799 | 1,078 | N/A |
| 6/30/2023 | 8,846 | 431 | 1,185 | 1,408 | N/A |
| 3/31/2023 | 8,231 | 408 | 1,354 | 1,551 | N/A |
| 12/31/2022 | 7,514 | 374 | 410 | 1,191 | N/A |
| 9/30/2022 | 6,277 | 300 | 63 | 1,018 | N/A |
| 6/30/2022 | 5,862 | 268 | -177 | 780 | N/A |
| 3/31/2022 | 5,518 | 267 | -280 | 691 | N/A |
| 12/31/2021 | 5,235 | 301 | 359 | 744 | N/A |
| 9/30/2021 | 4,947 | 276 | 506 | 724 | N/A |
| 6/30/2021 | 4,737 | 262 | 329 | 536 | N/A |
| 3/31/2021 | 4,578 | 262 | 179 | 339 | N/A |
| 12/31/2020 | 4,466 | 251 | 184 | 317 | N/A |
| 9/30/2020 | 4,213 | 215 | 186 | 315 | N/A |
| 12/31/2019 | 3,529 | 168 | 204 | 338 | N/A |
| 12/31/2018 | 2,766 | 134 | 89 | 193 | N/A |
| 12/31/2017 | 2,347 | 95 | N/A | 206 | N/A |
| 12/31/2016 | 2,054 | 71 | N/A | 145 | N/A |
| 12/31/2015 | 1,844 | 18 | N/A | -16 | N/A |
| 12/31/2014 | 1,667 | 17 | N/A | 66 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 605266's forecast earnings growth (21% per year) is above the savings rate (2.9%).
Earnings vs Market: 605266's earnings (21% per year) are forecast to grow slower than the CN market (23.3% per year).
High Growth Earnings: 605266's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 605266's revenue (20% per year) is forecast to grow faster than the CN market (14.1% per year).
High Growth Revenue: 605266's revenue (20% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 605266's Return on Equity is forecast to be low in 3 years time (16.9%).